Halozyme to Report Third Quarter 2025 Financial and Operating Results

Rhea-AI Summary

Halozyme (NASDAQ: HALO) will release its third quarter 2025 financial and operating results on Monday, November 3, 2025 following the close of trading.

The company will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT / 4:30 p.m. ET to discuss results. The call requires pre-registration via the provided link and a live webcast and replay will be available in the Investors section of Halozyme's website.

SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading.

Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137280.

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-third-quarter-2025-financial-and-operating-results-302589996.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme (HALO) report Q3 2025 results?

Halozyme will release Q3 2025 financial and operating results on Monday, November 3, 2025 following the close of trading.

What time is the Halozyme (HALO) Q3 2025 conference call?

The conference call is scheduled for November 3, 2025 at 1:30 p.m. PT / 4:30 p.m. ET.

How can investors access the Halozyme (HALO) November 3, 2025 call?

Investors may access the live call with pre-registration via the provided registration link and via a live webcast in the company's Investors website section.

Will there be a replay of the Halozyme (HALO) Q3 2025 conference call?

Yes. A live webcast and replay of the conference call will be available through the Investors section of Halozyme's website.

Is the Q3 2025 Halozyme (HALO) results release scheduled before or after the conference call?

The results will be released following the close of trading on November 3, 2025, before the conference call later that day.

What ticker should investors use to follow Halozyme ahead of the November 3, 2025 release?

Use the NASDAQ ticker HALO to follow Halozyme market activity and filings ahead of the release.